floxacillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, 6-aminopenicillanic acid derivatives	1183	5250-39-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: floxacillin fluocloxacilin flucloxacillin fluoxacillin flucloxacillin sodium	Antibiotic analog of CLOXACILLIN. Molecular weight: 453.87 Formula: C19H17ClFN3O5S CLOGP: 2.70 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 112.74 ALOGS: -3.92 ROTB: 3

Molecule

Description

Molfile Inchi Smiles

Synonyms:

floxacillin
fluocloxacilin
flucloxacillin
fluoxacillin
flucloxacillin sodium

Antibiotic analog of CLOXACILLIN.

Molecular weight: 453.87
Formula: C19H17ClFN3O5S
CLOGP: 2.70
LIPINSKI: 0
HAC: 8
HDO: 2
TPSA: 112.74
ALOGS: -3.92
ROTB: 3

Drug dosage:

Dose	Unit	Route
2	g	O
2	g	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	146.96 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.19 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1962	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metabolic acidosis	313.06	25.57	127	5281	38698	50561018
Drug interaction	131.06	25.57	132	5276	199489	50400227
Cellulitis	95.91	25.57	71	5337	70727	50528989
Pyroglutamate increased	89.97	25.57	18	5390	402	50599314
Pyroglutamic acidosis	77.24	25.57	16	5392	427	50599289
Neutropenic sepsis	55.31	25.57	28	5380	14119	50585597
Jaundice	48.58	25.57	32	5376	26397	50573319
Swelling face	48.22	25.57	42	5366	52553	50547163
Dermatitis allergic	43.46	25.57	23	5385	12697	50587019
Rash erythematous	40.62	25.57	32	5376	34820	50564896
Perforation	40.49	25.57	11	5397	953	50598763
Ejection fraction decreased	40.43	25.57	25	5383	18495	50581221
Hypokalaemia	38.16	25.57	47	5361	87945	50511771
Eczema herpeticum	36.91	25.57	7	5401	117	50599599
Lip swelling	36.13	25.57	26	5382	24710	50575006
Vulvovaginal inflammation	30.66	25.57	8	5400	594	50599122
Hiccups	30.05	25.57	10	5398	1729	50597987
Anterior interosseous syndrome	29.81	25.57	4	5404	4	50599712
Clostridium difficile infection	28.87	25.57	23	5385	25416	50574300
Polyhydramnios	28.56	25.57	10	5398	2015	50597701
Swollen tongue	28.54	25.57	24	5384	28606	50571110
Lower respiratory tract infection	27.82	25.57	42	5366	95159	50504557
Vascular device infection	27.40	25.57	12	5396	4372	50595344
Drug-induced liver injury	26.87	25.57	23	5385	28072	50571644
Angiodermatitis	26.81	25.57	5	5403	76	50599640
Acute haemorrhagic oedema of infancy	26.14	25.57	4	5404	16	50599700

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	133.52	21.20	148	3869	197237	29373273
Metabolic acidosis	121.42	21.20	71	3946	37591	29532919
Pyroglutamate increased	81.62	21.20	16	4001	249	29570261
Pyroglutamic acidosis	68.83	21.20	14	4003	265	29570245
Drug reaction with eosinophilia and systemic symptoms	67.75	21.20	44	3973	27948	29542562
Immunosuppressant drug level decreased	62.80	21.20	17	4000	1141	29569369
Drug level decreased	53.80	21.20	23	3994	6224	29564286
Kounis syndrome	42.72	21.20	14	4003	1815	29568695
Stevens-Johnson syndrome	37.61	21.20	25	3992	16472	29554038
Genitalia external ambiguous	37.02	21.20	8	4009	205	29570305
Congenital bladder anomaly	35.04	21.20	8	4009	265	29570245
Acute kidney injury	34.56	21.20	96	3921	265171	29305339
Foetal hypokinesia	32.45	21.20	8	4009	370	29570140
Neonatal respiratory depression	31.76	21.20	8	4009	404	29570106
Heart transplant rejection	31.75	21.20	10	4007	1141	29569369
Osteomyelitis salmonella	29.94	21.20	5	4012	29	29570481
Penile exfoliation	29.62	21.20	6	4011	111	29570399
Inhibitory drug interaction	29.35	21.20	10	4007	1460	29569050
Lip swelling	24.00	21.20	17	4000	12393	29558117
Allergy test positive	23.43	21.20	4	4013	27	29570483
Nightmare	22.92	21.20	16	4001	11401	29559109
Blister	22.76	21.20	20	3997	19886	29550624

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metabolic acidosis	388.67	19.35	195	9265	70763	64418509
Drug interaction	244.74	19.35	282	9178	361801	64127471
Pyroglutamate increased	166.07	19.35	34	9426	614	64488658
Pyroglutamic acidosis	133.36	19.35	29	9431	707	64488565
Cellulitis	91.34	19.35	89	9371	93568	64395704
Drug level decreased	66.86	19.35	33	9427	11470	64477802
Immunosuppressant drug level decreased	58.13	19.35	18	9442	1797	64487475
Lip swelling	57.13	19.35	43	9417	31864	64457408
Drug reaction with eosinophilia and systemic symptoms	55.59	19.35	53	9407	54164	64435108
Clostridium difficile infection	50.28	19.35	42	9418	36121	64453151
Dermatitis allergic	47.83	19.35	29	9431	15080	64474192
Neutropenic sepsis	47.62	19.35	34	9426	23238	64466034
Acute kidney injury	47.42	19.35	159	9301	449081	64040191
Swelling face	46.33	19.35	50	9410	59116	64430156
Stevens-Johnson syndrome	43.97	19.35	38	9422	34211	64455061
Jaundice	43.35	19.35	44	9416	48468	64440804
Mouth swelling	39.99	19.35	18	9442	5089	64484183
Rash erythematous	39.66	19.35	42	9418	48591	64440681
Rash	36.33	19.35	148	9312	458401	64030871
Perforation	35.15	19.35	11	9449	1137	64488135
Kounis syndrome	34.78	19.35	14	9446	3011	64486261
Swollen tongue	33.62	19.35	33	9427	34921	64454351
Eczema herpeticum	30.76	19.35	7	9453	211	64489061
Heart transplant rejection	29.89	19.35	10	9450	1277	64487995
Penile exfoliation	29.53	19.35	6	9454	104	64489168
Angioedema	28.49	19.35	40	9420	61781	64427491
Polyhydramnios	28.48	19.35	10	9450	1477	64487795
Lower respiratory tract infection	28.04	19.35	50	9410	94564	64394708
Osteomyelitis salmonella	27.84	19.35	5	9455	43	64489229
Hypokalaemia	27.05	19.35	57	9403	121846	64367426
Chromaturia	26.84	19.35	24	9436	22587	64466685
Acidosis	25.42	19.35	21	9439	17774	64471498
Angiodermatitis	25.35	19.35	5	9455	74	64489198
Malaise	24.60	19.35	119	9341	396128	64093144
Death	24.41	19.35	21	9439	482684	64006588
Congenital bowing of long bones	24.15	19.35	4	9456	20	64489252
Anaphylactic reaction	23.92	19.35	39	9421	68625	64420647
Ejection fraction decreased	23.77	19.35	25	9435	28682	64460590
Anterior interosseous syndrome	23.53	19.35	4	9456	24	64489248
Strawberry tongue	23.53	19.35	4	9456	24	64489248
Completed suicide	22.78	19.35	3	9457	224411	64264861
Repetitive strain injury	22.12	19.35	5	9455	146	64489126
Skin exfoliation	22.11	19.35	30	9430	44855	64444417
Blister	21.72	19.35	41	9419	80926	64408346
Pustule	21.71	19.35	8	9452	1357	64487915
Liver function test abnormal	21.04	19.35	34	9426	59367	64429905
Vulvovaginal inflammation	20.74	19.35	6	9454	474	64488798
Tubulointerstitial nephritis	20.55	19.35	24	9436	30885	64458387
Acute haemorrhagic oedema of infancy	20.29	19.35	4	9456	59	64489213
Vascular device infection	19.91	19.35	12	9448	6168	64483104
Clostridium difficile colitis	19.55	19.35	22	9438	27201	64462071

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01CF05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase resistant penicillins
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.76	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN	IC50	6.25	WOMBAT-PK
Matrix metalloproteinase-9	Enzyme	P14780	MMP9_HUMAN	IC50	4.19	WOMBAT-PK
Penicillin-binding protein 1A	Enzyme		PBPA_CLOPE			WOMBAT-PK

External reference:

ID	Source
N0000167002	NUI
D01249	KEGG_DRUG
C0016267	UMLSCUI
CHEBI:5098	CHEBI
CHEMBL222645	ChEMBL_ID
D005436	MESH_DESCRIPTOR_UI
DB00301	DRUGBANK_ID
10910	IUPHAR_LIGAND_ID
21319	PUBCHEM_CID
235750	RXNORM
003516	NDDF
003517	NDDF
387544009	SNOMEDCT_US
426208000	SNOMEDCT_US
96067005	SNOMEDCT_US
2308	INN_ID
43B2M34G2V	UNII

Pharmaceutical products:

None